Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 7/20 | 0.51 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.51 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.51 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505464 | 0.90 | VEGFA (0.61) | VEGFAEGLN1MEN1KMT2AMGLL | |
| SCHEMBL20971874 | 0.89 | VEGFA (0.57) | VEGFAEGLN1MEN1KMT2AMGLL | |
| SCHEMBL17513187 | 0.89 | VEGFA (0.59) | VEGFAEGLN1MEN1KMT2AMGLL | |
| SCHEMBL12432212 | 0.88 | KDM1A (0.57) | VEGFAEGLN1KMT2AMGLLSETD7 | |
| SCHEMBL15093856 | 0.87 | VEGFA (0.57) | VEGFAEGLN1MEN1KMT2AMGLL | |
| SCHEMBL18917684 | 0.86 | VEGFA (0.59) | VEGFAEGLN1MEN1KMT2AMGLL | |
| SCHEMBL15264098 | 0.86 | VEGFA (0.56) | VEGFAEGLN1MEN1KMT2AMGLL | |
| SCHEMBL21571768 | 0.85 | PLA2G7 (0.51) | VEGFAEGLN1MEN1KMT2AMGLL | |
| SCHEMBL25388730 | 0.85 | KCNK3 (0.52) | VEGFAEGLN1MEN1KMT2ASETD7 | |
| SCHEMBL15093853 | 0.85 | MGLL (0.67) | VEGFAEGLN1MEN1KMT2AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118946556-A | DGK targeting compounds and uses thereof | 阿维纳斯运营公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3541821-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | VEGFA 4885/4885EGLN1 1615/4885MEN1 2056/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | VEGFA 4885/4885EGLN1 1615/4885MEN1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.